05.11.2014 • NewsIneosshale-gasEvergas

Ineos Orders Two More Ethane Transport Vessels

For a second time, Ineos has increased the number of vessels required to transport US shale-gas derived ethane to its planned terminals at Grangemouth, Scotland, and Rafnes, Norway.

In May of this year, the Swiss-based group said it would order two additional "Dragon Ships" from supplier Evergas of Copenhagen, Denmark, raising the number then from four to six.

The vessels are also capable of transporting LPG, LNG and petrochemical gases including ethylene.

Ineos' terminal and ethane storage tank at Rafnes is nearing completion and expected to be fully operational some time next year. The tank and terminal at Grangemouth is due to be completed in 2016.

David Thompson, chief operating officer of Ineos Trading & Shipping, called the top-up ship order "another important milestone in our plan to bring the benefits of shale US gas economics to our European sites." Ethane is "the most competitive feedstock in Europe," Thompson remarked.

In October 2012, Ineos signed the first-ever agreement to ship US ethane to Europe. In the mean time, a number of other European companies have followed suit.

The formerly British chemical group also has taken stakes in two shale gas exploration licenses covering areas near its Grangemouth production complex.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.